Literature DB >> 16598606

[Drug treatment of chronic heart failure].

M Böhm1, N Werner, M Kindermann.   

Abstract

Drug treatment of chronic heart failure is undergoing continuous modifications according to the data of new trials. Treatment has to be adjusted to current guidelines. The state of the art of medical treatment of chronic heart failure is addressed in this report.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16598606     DOI： 10.1007/s00392-006-2008-9

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


  47 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group.

Authors: 
Journal:  JAMA       Date:  1988 Jan 22-29       Impact factor: 56.272

3.  Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

Authors: 
Journal:  Am J Cardiol       Date:  1990-10-01       Impact factor: 2.778

Review 4.  Beta-adrenergic blocker mortality trials in congestive heart failure.

Authors:  J R Teerlink; B M Massie
Journal:  Am J Cardiol       Date:  1999-11-04       Impact factor: 2.778

Review 5.  [Pathophysiology of heart failure today].

Authors:  Michael Böhm
Journal:  Herz       Date:  2002-03       Impact factor: 1.443

6.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.

Authors:  J N Cohn; S Ziesche; R Smith; I Anand; W B Dunkman; H Loeb; G Cintron; W Boden; L Baruch; P Rochin; L Loss
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

7.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

Authors:  Marcus D Flather; Marcelo C Shibata; Andrew J S Coats; Dirk J Van Veldhuisen; Aleksandr Parkhomenko; Joszef Borbola; Alain Cohen-Solal; Dan Dumitrascu; Roberto Ferrari; Philippe Lechat; Jordi Soler-Soler; Luigi Tavazzi; Lenka Spinarova; Jiri Toman; Michael Böhm; Stefan D Anker; Simon G Thompson; Philip A Poole-Wilson
Journal:  Eur Heart J       Date:  2005-01-09       Impact factor: 29.983

8.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

9.  Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study.

Authors:  U Goldbourt; S Behar; H Reicher-Reiss; M Zion; L Mandelzweig; E Kaplinsky
Journal:  Arch Intern Med       Date:  1993-02-08

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245
View more
  12 in total

Review 1.  Management of end stage heart failure.

Authors:  Erik B Friedrich; Michael Böhm
Journal:  Heart       Date:  2007-05       Impact factor: 5.994

2.  Beta blockers and glucose metabolism in chronic heart failure: friend or foe?

Authors:  W Doehner; S D Anker
Journal:  Clin Res Cardiol       Date:  2008-01       Impact factor: 5.460

3.  Heart failure and malignant ventricular tachyarrhythmias due to hereditary hemochromatosis with iron overload cardiomyopathy.

Authors:  A W Demant; A Schmiedel; R Büttner; T Lewalter; C Reichel
Journal:  Clin Res Cardiol       Date:  2007-08-20       Impact factor: 5.460

Review 4.  [Preoperative risk evaluation in heart failure].

Authors:  B Cremers; C Maack; M Böhm
Journal:  Internist (Berl)       Date:  2007-09       Impact factor: 0.743

5.  Clinical trial updates and hotline sessions presented at the Scientific Session 2007 of the American Heart Association.

Authors:  U Laufs; H Nef; H Möllmann; F Custodis; M Böhm
Journal:  Clin Res Cardiol       Date:  2007-12-18       Impact factor: 5.460

6.  Heart failure, aging and beta-blockers: the need for more data on tolerability and efficacy.

Authors:  Kevin Damman; Rudolf A de Boer; Dirk J van Veldhuisen
Journal:  Clin Res Cardiol       Date:  2008-09       Impact factor: 5.460

7.  Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective.

Authors:  Pamela Aidelsburger; Kristin Grabein; Volker Klauss; Jürgen Wasem
Journal:  Clin Res Cardiol       Date:  2007-10-25       Impact factor: 5.460

8.  The initial slope of the VCO2/VO2-curve (s1) in cardiopulmonary exercise testing is a strong and independent predictor of outcome in patients with previous myocardial infarction.

Authors:  Joerg Honold; Lenka Geiger; Birgit Assmus; Ulrich Fischer-Rasokat; Volker Schaechinger; Andreas M Zeiher; Ioakim Spyridopoulos
Journal:  Clin Res Cardiol       Date:  2008-08-11       Impact factor: 5.460

9.  Prognostic value of heart rate variability and ventricular arrhythmias during 13-year follow-up in patients with mild to moderate heart failure.

Authors:  Tom D J Smilde; Dirk J van Veldhuisen; Maarten P van den Berg
Journal:  Clin Res Cardiol       Date:  2009-02-13       Impact factor: 5.460

10.  Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial.

Authors:  Hans-Dirk Düngen; Svetlana Apostolović; Simone Inkrot; Elvis Tahirović; Florian Krackhardt; Milan Pavlović; Biljana Putniković; Mitja Lainscak; Götz Gelbrich; Frank Edelmann; Rolf Wachter; Thomas Eschenhagen; Finn Waagstein; Ferenc Follath; Mathias Rauchhaus; Wilhelm Haverkamp; Karl-Josef Osterziel; Rainer Dietz
Journal:  Clin Res Cardiol       Date:  2008-06-09       Impact factor: 5.460
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.